CAR T Companion Tool
Patient Education

What Patients Need to Know

Have you or a loved one been diagnosed with non-Hodgkin lymphoma? Non-Hodgkin lymphoma is one of the most common cancers in the United States, with nearly 80,000 new diagnoses estimated for 2026.[1] This FAQ aims to answer commonly asked questions about the disease and CAR T-cell therapy.

Provided by Integritas Communications. Information sourced from the American Cancer Society, National Cancer Institute, and peer-reviewed literature. This content is for educational purposes only and does not substitute for professional medical advice.

References

  1. 1.American Cancer Society. All About Cancer: Key Statistics for Non-Hodgkin Lymphoma. Last updated January 13, 2026. Accessed July 24, 2026.
  2. 2.American Cancer Society. All About Cancer: What Is Non-Hodgkin Lymphoma? Last updated February 15, 2024. Accessed July 24, 2026.
  3. 3.National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Non-Hodgkin Lymphoma. Accessed July 24, 2026.
  4. 4.American Cancer Society. All About Cancer: Tests for Non-Hodgkin Lymphoma. Last updated February 15, 2024. Accessed July 24, 2026.
  5. 5.PDQ® Adult Treatment Editorial Board. Non-Hodgkin Lymphoma Treatment (PDQ®)—Patient Version. Bethesda, MD: National Cancer Institute. Updated August 22, 2024. Accessed July 24, 2026.
  6. 6.Sheikh S, et al. Biomedicines. 2022;10(8):1960.
  7. 7.Feins S, et al. Am J Hematol. 2019;94(S1):S3-S9.
  8. 8.NCI. About Cancer: CAR T-Cells: Engineering Patients' Immune Cells to Treat Their Cancers. Last updated February 26, 2025. Accessed July 24, 2026.
  9. 9.US Food and Drug Administration. FDA Safety Communication: FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous CAR T-cell Immunotherapies. Released June 26, 2025. Accessed July 24, 2026.
  10. 10.Adkins S. J Adv Pract Oncol. 2019;10(suppl 3):21-28.
  11. 11.American Cancer Society. Education Materials for Your Patients. Accessed July 24, 2026.